-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $27

Benzinga·06/18/2026 13:17:53
Listen to the news
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $22 to $27.